Merck' anti-PD-1 Keytruda fails as a monotherapy with chemoMay 09, 2024 - "Used as an adjuvant treatment with chemotherapy, with or without radiotherapy for newly diagnosed high-risk patients, the anti-PD-1 treatment did not meet the primary endpoint of disease-free survival compared to placebo at the interim analysis."
That announcement came on the heels of back-to-back Keytruda failures in non-small cell lung cancer (NSCLC). In December, the company announced that combined with its experimental anti-TIGIT antibody vibostolimab, the anti-PD1 failed to improve progression free survival in NSCLC patients. The same day, a trial of Keytruda plus AstraZeneca’s Lynparza failed to elicit significant improvement in overall survival in metastatic squamous NSCLC. Then, in March, the company announced that the Lynparza combination fell short of dual primary endpoints in specific patients with metastatic non-squamous NSCLC.
https://www.biospace.com/article/keytruda-strikes-out-again-for-endometrial-cancer-with-phase-iii-fail-/